The Journal of Immunology, Vol 138, Issue 1 51-57, Copyright © 1987 by American Association of Immunologists

ARTICLES

Lethal graft-vs-host disease across major histocompatibility barriers: requirement for leucyl-leucine methyl ester sensitive cytotoxic T cells

DL Thiele, MR Charley, JA Calomeni and PE Lipsky

L-leucyl-L-leucine methyl ester (Leu-Leu-OMe) is selectively toxic for human natural killer (NK) cells and cytotoxic T lymphocytes (CTL) at both the precursor and effector stage of differentiation. The present studies explored the effects of Leu-Leu-OMe on murine spleen cell function. Leu-Leu-OMe exposure removed NK function from murine spleen cells but spared their capacity to proliferate in response to lipopolysaccharide and Con A. The capacity to generate CTL from both L3T4 (+) and Lyt-2 (+) precursors was lost after Leu-Leu-OMe treatment, whereas alloantigen-induced proliferation and interleukin 2 (IL 2) production by L3T4 (+) T helper cells remained intact. Lethal graft vs host disease (GVHD), which developed in irradiated (C57BL/6 X DBA/2)F1 recipients of C57BL/6 bone marrow and spleen cells was completely prevented by Leu-Leu-OMe treatment of donor cells. In contrast depletion of Lyt-2 positive cells from the donor inoculum did not prevent acute GVHD in this fully major histo-compatibility complex (MHC) incompatible strain combination. However, Leu-Leu-OMe treatment of the Lyt-2 depleted inoculum completely prevented lethal GVHD, although the treated cells retained the capacity to proliferate and secrete IL 2 normally after in vitro stimulation with (C57BL/6 X DFA/2)F1 spleen cells. These findings indicate that L3T4 (+) T helper cells alone are unable to initiate lethal GVHD in this H-2 incompatible strain combination. Rather, lethal GVHD requires the transfer of a Leu- Leu-OMe sensitive T cell subset, likely to be thymus educated pre-CTL. Leu-Leu-OMe treatment should provide a useful way to delineate subpopulations of cells involved in the production of lethal GVHD and an approach to preventing this complication of bone marrow transplantation.

This article has been cited by other articles:

				G. R. Brown, E. L. Lee, and D. L. Thiele TNF Enhances CD4+ T Cell Alloproliferation, IFN-{gamma} Responses, and Intestinal Graft-Versus-Host Disease by IL-12-Independent Mechanisms J. Immunol., May 15, 2003; 170(10): 5082 - 5088. [Abstract] [Full Text] [PDF]

				G. R. Brown, E. Lee, and D. L. Thiele TNF-TNFR2 Interactions Are Critical for the Development of Intestinal Graft-Versus-Host Disease in MHC Class II-Disparate (C57BL/6J->C57BL/6J x bm12)F1 Mice J. Immunol., March 15, 2002; 168(6): 3065 - 3071. [Abstract] [Full Text] [PDF]

				D. Cilloni, C. Carlo-Stella, F. Falzetti, G. Sammarelli, E. Regazzi, S. Colla, V. Rizzoli, F. Aversa, M. F. Martelli, and A. Tabilio Limited engraftment capacity of bone marrow-derived mesenchymal cells following T-cell-depleted hematopoietic stem cell transplantation Blood, November 15, 2000; 96(10): 3637 - 3643. [Abstract] [Full Text] [PDF]

				P. Bobe, K. Benihoud, D. Grandjon, P. Opolon, L. L. Pritchard, and R. Huchet Nitric Oxide Mediation of Active Immunosuppression Associated With Graft-Versus-Host Reaction Blood, August 1, 1999; 94(3): 1028 - 1037. [Abstract] [Full Text] [PDF]

				C. L. Mabee, M. J. McGuire, and D. L. Thiele Dipeptidyl Peptidase I and Granzyme A Are Coordinately Expressed During CD8+ T Cell Development and Differentiation J. Immunol., June 15, 1998; 160(12): 5880 - 5885. [Abstract] [Full Text] [PDF]

				G. Shankar, J. Scott Bryson, C. Darrell Jennings, P. E. Morris, and D. A. Cohen Idiopathic Pneumonia Syndrome in Mice after Allogeneic Bone Marrow Transplantation Am. J. Respir. Cell Mol. Biol., February 1, 1998; 18(2): 235 - 242. [Abstract] [Full Text]

				Y.-G. Yang, J. J. Sergio, D. A. Pearson, G. L. Szot, A. Shimizu, and M. Sykes Interleukin-12 Preserves the Graft-Versus-Leukemia Effect of Allogeneic CD8 T Cells While Inhibiting CD4-Dependent Graft-Versus-Host Disease in Mice Blood, December 1, 1997; 90(11): 4651 - 4660. [Abstract] [Full Text] [PDF]